KHKatsuhiko Hagi

Katsuhiko Hagi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katsuhiko Hagi has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data

    byĀ Katsuhiko Hagi, Kazumasa Yoshida, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki

    Introduction: Identifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement. Methods: Regression tree and random forest methods identified baseline characteristics predictive of HbA1c improvement. Partial dependence plots (PDP) visualized the relationship between HbA1c change and continuous variables deemed important by Boruta. Results: For monotherapy, key predictors were baseline HbA1c, hypertension, smoking, type 2 diabetes duration, body mass index (BMI), low‐density lipoprotein‐cholesterol (LDL‐C), metabolic syndrome, and estimated glomerular filtration rate. Nonsmokers with HbA1c ≄8.35% and LDL‐C < 3.26 mmol/L at baseline showed the greatest improvement in HbA1c (āˆ’1.24%). Random forest analysis and Boruta identified baseline HbA1c, BMI, fatty liver index, smoking, and hypertension as significant predictors of HbA1c improvement. PDPs identified a positive correlation between higher baseline HbA1c, and a negative correlation between BMI and fatty liver index, and HbA1c improvement. For imeglimin add‐on to insulin therapy, key predictors were BMI, age, LDL‐C, type 2 diabetes duration, systolic blood pressure, and alanine transaminase (ALT). Patients with BMI <25.9, LDL‐C < 2.68 mmol/L, and ALT <21 U/L showed the greatest HbA1c improvement (āˆ’1.48%). Random forest analysis and Boruta confirmed BMI, age, and LDL‐C as significant predictors. PDPs identified a positive correlation between older age, and a negative correlation between higher BMI and LDL‐C, and HbA1c improvement. Conclusions: Machine learning effectively identified baseline characteristics predictive of HbA1c response to imeglimin, supporting the potential for personalized type 2 diabetes treatment strategies.

  • Open Access

    Long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52‐week postmarketing clinical study ( TWINKLE )

    byĀ Tetsuya Babazono, Takeshi Osonoi, Hideki Okamoto, Yukiko Onishi, Shinya Nakamoto, Masayuki Kashima, Daiji Kawanami, Eitaro Nakashima, Kei Watabe, Noriko Nunami, et al.

    Aim: To evaluate the long‐term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD). Materials and Methods: This open‐label, single‐arm, multicenter, phase 4 study (TWINKLE) enrolled individuals with T2D and estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m 2 , treated with ≤1 oral hypoglycemic agent. Participants received 500 mg of imeglimin twice daily if eGFR was 15 to 2 or 500 mg once daily if eGFR was 2 , as monotherapy or in combination with their existing hypoglycemic agent, for 52 weeks. Dose adjustments were permitted based on safety and eGFR. Results: Among 60 participants (CKD stages: G3b: n = 42; G4: n = 16; G5: n = 2), adverse events (AEs) occurred in 41 participants (68.3%), with no increased incidence across CKD stages. The most common AE was diarrhea ( n = 6, 10.0%). Baseline mean (SD) HbA1c, glycated albumin (GA), and fasting plasma glucose (FPG) levels were 7.59% (0.68%), 22.53% (3.27%), and 151.8 (28.86) mg/dL, respectively. At week 24, mean (SD) changes from baseline were āˆ’0.53% (0.51%) for HbA1c, āˆ’2.37% (2.08%) for GA, and āˆ’13.6 (20.87) mg/dL for FPG. At week 52 (last observation carried forward [LOCF]), mean changes were āˆ’0.26% (0.88%), āˆ’1.59% (3.04%), and āˆ’7.0 (31.17) mg/dL. The proportion achieving HbA1c < 7.0% increased from 13.3% at baseline to 50.0% at week 52 (LOCF). Conclusions: This study confirmed the favorable safety profile and sustained glycemic efficacy of imeglimin in Japanese individuals with T2D and CKD stages G3b–5, supporting its use with dose adjustment in this population.


  • Open Access

    Gastrointestinal symptoms in patients receiving imeglimin in combination with metformin: A post‐hoc analysis of imeglimin clinical trial data

    byĀ Jumpei Ito, Katsuhiko Hagi, Kenji Kochi, Kohjiro Ueki, Hirotaka Watada, Kohei Kaku

    Introduction: An increased rate of gastrointestinal (GI) symptoms is reported in patients with type 2 diabetes receiving imeglimin plus metformin vs monotherapy or in combination with other antidiabetic drugs. This post‐hoc analysis explored GI symptom incidence, risk factors for their occurrence, and the impact on therapeutic efficacy during imeglimin and metformin combination therapy.Materials and Methods: Data were derived from the 52‐week, open‐label, phase 3 TIMES‐2 trial in Japanese type 2 diabetes patients. Patients in the imeglimin plus metformin group were divided into two subgroups based on the presence of GI symptoms and diarrhea, with efficacy and safety assessed. Factors associated with their occurrence were explored using multivariate logistic regression analysis.Results: Of 64 patients analyzed, GI symptoms and diarrhea occurred in 40.6% (n = 26) and 17.2% (n = 11) of patients, respectively. Metformin dose and patient age did not significantly affect their incidence. Events occurred more frequently within the first 4 months of treatment. Approximately half resolved within 1 week, and most were mild. Type 2 diabetes duration P = 0.039). Significant hypoglycemic effects were observed from baseline, irrespective of GI symptoms or diarrhea. However, the degree of HbA1c improvement tended to be greater in patients with GI symptoms and diarrhea.Conclusions: Increased awareness regarding the potential for GI symptoms, including diarrhea, during imeglimin plus metformin combination therapy is warranted. This data will provide clinicians with useful information regarding symptomatic treatment when it occurs and help determine whether to continue treatment administration and is expected to improve patient adherence.


  • Open Access

    Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data‐driven cluster analysis: A post‐hoc analysis of imeglimin clinical trial data

    byĀ Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki

    Aim: To explore differences in imeglimin response among type 2 diabetes (T2D) patient clusters using data‐driven cluster analysis. Methods: Data‐driven cluster analysis (non‐hierarchical k‐means clustering) was performed on randomized, double‐blind, imeglimin monotherapy and adjunctive (to insulin) therapy trials based on four baseline variables: (1) disease duration; (2) body mass index (BMI); (3) HbA1c; and (4a) homeostatic model assessment of β‐cell function (HOMA‐β) (monotherapy trials) or (4b) insulin total daily dose (adjunctive trial). Results: Four clusters were identified with distinct clinical characteristics in both monotherapy (1‐4) and adjunctive therapy (I‐IV) trials; clusters 1 and I had lower values across all four indices versus the overall population, clusters 2 and II had a longer diabetes duration, cluster 3 had higher baseline BMI and HOMA‐β, and cluster III had higher baseline BMI and insulin total daily dose, while clusters 4 and IV had higher baseline HbA1c. Between‐group differences in HbA1c change (95% confidence interval) and effect size (ES) at week 24 varied considerably by cluster (cluster 1: āˆ’0.82 [āˆ’1.00, āˆ’0.63], ES = 1.47; cluster 2: āˆ’0.64 [āˆ’0.89, āˆ’0.39], ES = 1.18; cluster 3: āˆ’0.86 [āˆ’1.38, āˆ’0.33], ES = 0.84; cluster 4: āˆ’1.27 [āˆ’1.73, āˆ’0.82], ES = 1.44). For imeglimin adjunctive therapy, HbA1c improvements were significant versus placebo at week 16, excluding cluster III (cluster I: āˆ’0.63 [āˆ’0.95, āˆ’0.31], ES = 0.88; cluster II: āˆ’0.66 [āˆ’1.02, āˆ’0.30], ES = 1.13; cluster III: āˆ’0.31 [āˆ’0.73, 0.11], ES = 0.46; cluster IV: āˆ’0.82 [āˆ’1.29, āˆ’0.35], ES = 0.99). Conclusions: Differences in imeglimin response were observed among T2D patient clusters. Patient stratification may help with selection of those most probable to respond to imeglimin.


  • Open Access

    Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus

    byĀ Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki

    Aims/Introduction: To investigate the effect of patient characteristics on imeglimin effectiveness in Japanese patients with type 2 diabetes mellitus.Materials and Methods: Data were pooled from two randomized, placebo‐controlled, 24‐week, double‐blind studies of imeglimin monotherapy in Japanese adults with type 2 diabetes mellitus, with the proportion of responders (glycated hemoglobin [HbA1c] < 7.0%) and sustained responders (i.e., achieved and maintained response) in the imeglimin 1,000 mg twice daily group calculated at each visit. Patient factors significantly (P < 0.05) correlated with response were explored through multivariate logistic regression. Subgroup analyses compared the efficacy of imeglimin in patients with a HbA1c improvement less than or equal to āˆ’0.3% (early responders) versus greater than āˆ’0.3% (early non‐responders) at week 4.Results: A total of 38.0% of imeglimin‐treated patients and 7.2% of placebo‐treated patients were responders (P < 0.001, number needed to treat = 4). The proportion of sustained responders at weeks 4, 8, 12, 16 and 20 was 10.6, 19.0, 24.0, 25.7 and 29.1%, respectively (>70% of responders at each visit). Improvements in HbA1c and fasting glucose were significantly greater in early responders versus early non‐responders from week 4; between‐group differences remained significant to week 24. Older age (odds ratio 1.09, 95% confidence interval 1.04–1.14; P < 0.001); treatment‐naĆÆve status vs previous treatment (odds ratio 3.70, 95% confidence interval 1.55–8.82; P = 0.003), and lower baseline HbA1c (odds ratio 0.06, 95% confidence interval 0.02–0.16; P < 0.001) predicted response.Conclusions: A significantly higher proportion of patients receiving imeglimin 1,000 mg twice daily monotherapy were responders versus placebo. Most (>70%) were sustained responders, suggesting that response is fairly predictable. Older age, treatment‐naĆÆve status and early treatment response significantly predicted imeglimin effectiveness.


  • Top Cited Papers
    Open Access

    Telepsychiatry versus face-to-face treatment: systematic review and meta-analysis of randomised controlled trials

    byĀ Katsuhiko Hagi, Shunya Kurokawa, Akihiro Takamiya, Mayu Fujikawa, Shotaro Kinoshita, Mari Iizuka, Shota Furukawa, Yoko Eguchi, Taishiro Kishimoto

    Background: The COVID-19 pandemic has transformed healthcare significantly and telepsychiatry is now the primary means of treatment in some countries.Aims: To compare the efficacy of telepsychiatry and face-to-face treatment.Method: A comprehensive meta-analysis comparing telepsychiatry with face-to-face treatment for psychiatric disorders. The primary outcome was the mean change in the standard symptom scale scores used for each psychiatric disorder. Secondary outcomes included all meta-analysable outcomes, such as all-cause discontinuation and safety/tolerability.Results: We identified 32 studies (n = 3592 participants) across 11 mental illnesses. Disease-specific analyses showed that telepsychiatry was superior to face-to-face treatment regarding symptom improvement for depressive disorders (k = 6 studies, n = 561; standardised mean difference s.m.d. = āˆ’0.325, 95% CI āˆ’0.640 to āˆ’0.011, P = 0.043), whereas face-to-face treatment was superior to telepsychiatry for eating disorder (k = 1, n = 128; s.m.d. = 0.368, 95% CI 0.018–0.717, P = 0.039). No significant difference was seen between telepsychiatry and face-to-face treatment when all the studies/diagnoses were combined (k = 26, n = 2290; P = 0.248). Telepsychiatry had significantly fewer all-cause discontinuations than face-to-face treatment for mild cognitive impairment (k = 1, n = 61; risk ratio RR = 0.552, 95% CI 0.312–0.975, P = 0.040), whereas the opposite was seen for substance misuse (k = 1, n = 85; RR = 37.41, 95% CI 2.356–594.1, P = 0.010). No significant difference regarding all-cause discontinuation was seen between telepsychiatry and face-to-face treatment when all the studies/diagnoses were combined (k = 27, n = 3341; P = 0.564).Conclusions: Telepsychiatry achieved a symptom improvement effect for various psychiatric disorders similar to that of face-to-face treatment. However, some superiorities/inferiorities were seen across a few specific psychiatric disorders, suggesting that its efficacy may vary according to disease type.


  • Open Access

    Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta‐analysis of randomized controlled trials

    byĀ Katsuhiko Hagi, Masahiro Nitta, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki

    Aims/Introduction: This meta‐analysis aimed to evaluate the efficacy and safety/tolerability of imeglimin, a novel oral antihyperglycemic agent, administered as monotherapy and adjunctive therapy in patients with type 2 diabetes mellitus.Materials and Methods: Parallel‐group randomized controlled trials comparing imeglimin with placebo in adults with type 2 diabetes mellitus were included. Risk ratios or weighted mean differences (WMD) and 95% confidence intervals (CIs) were calculated using random effects models. The primary outcome for efficacy was the change in glycated hemoglobin (HbA1c). Secondary outcomes included other efficacy‐related outcomes, specific adverse events, and changes in body weight and lipid parameters.Results: Nine randomized controlled trials (n = 1,655) were included. When analyzed by dose, there was a significant difference in glycated hemoglobin (%) between imeglimin monotherapy and placebo at doses >1,000 mg twice daily (1,000 mg: studies N = 3, patients n = 517, WMD = āˆ’0.714, P < 0.001; 1,500 mg: N = 5, n = 448, WMD = āˆ’0.531, P = 0.020; 2,000 mg: N = 1, n = 149, WMD = āˆ’0.450, P = 0.005). Imeglimin adjunctive therapy significantly improved glycated hemoglobin over placebo at doses of 1,000 mg (N = 1, n = 214, WMD = āˆ’0.600, P < 0.001) and 1,500 mg (N = 2, n = 324, WMD = āˆ’0.576, P < 0.001). Subgroup analysis of the primary outcome showed that imeglimin was effective regardless of chronic kidney disease category, with studies carried out in Japan and in patients with lower body mass index showing a trend toward improved imeglimin efficacy. There were no significant differences between imeglimin and placebo in the risk of all‐cause discontinuation and the proportion of patients who presented with at least one adverse event.Conclusions: Imeglimin is efficacious, safe, and well tolerated as monotherapy and adjunctive therapy.


  • Open Access

    Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post‐hoc analysis of two randomized, placebo‐controlled trials

    byĀ Katsuhiko Hagi, Kenji Kochi, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki

    Aims/Introduction: Substantial variability in demographic and clinical characteristics exists among patients with type 2 diabetes mellitus, which may impact treatment. This post‐hoc analysis evaluated the efficacy and safety of imeglimin 1,000 mg twice daily (BID) monotherapy in type 2 diabetes mellitus patients according to demographic and clinical characteristics.Materials and Methods: Data were pooled from two placebo‐controlled, 24 week, randomized, double‐blind studies in adults with type 2 diabetes mellitus. Outcomes (least squares mean [LSM] change in HbA1c from baseline to week 24, and safety) were analyzed according to subgroups based on demographics, clinical characteristics, and comorbidities.Results: The difference in LSM change in HbA1c from baseline to week 24 was statistically significant for imeglimin vs placebo in all patient subgroups analyzed (P < 0.05 each), including demographics (age, body mass index), clinical characteristics (duration of type 2 diabetes mellitus, chronic kidney disease [CKD] stage, and prior medication use) and comorbidities (hypertension, dyslipidemia, risk of hepatic fibrosis and liver function parameter status). A statistically significant separation from placebo in HbA1c was observed at week 4 and maintained through week 24. No new safety concerns were identified with imeglimin in any patient subpopulations.Conclusions: The efficacy and safety of imeglimin was demonstrated across patient subgroups, irrespective of baseline demographic and clinical characteristics. Our findings confirm the efficacy and safety of imeglimin across a broad spectrum of patients with type 2 diabetes mellitus.


  • Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression

    byĀ Melissa P. DelBello, Aditi Kadakia, Vincent Heller, Rajpal Singh, Katsuhiko Hagi, Tadashi Nosaka, Antony Loebel